Author(s):
Swati Lade, Nirmal Shah, Sushil Burle
Email(s):
swatilade09@gmail.com
DOI:
10.52711/0974-360X.2022.00554 
Address:
Swati Lade1*, Nirmal Shah1, Sushil Burle2
1Department of Pharmacy, Sumandeep Vidyapeeth, Piparia, Vadodara, Gujarat, India.
2Hi-Tech College of Pharmacy, Chandrapur, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 7,
Year - 2022
ABSTRACT:
Migraine is a very mysterious and much-misunderstood disorder characterized by pulsating headache in one side of the head in the form of attacks lasting from 4-48 hrs. It is a complex neurological condition, in this condition which can affect the whole body with many symptoms. However to cure this and effective treatment the nanostructured lipid carriers are used as widely nowadays. This use of structures ranges from the size 1-100nm with the main aim to develop the medicine to diagnose as accurately and effectively with less or no side effects. As we developed the stability and leakage of drugs is also improved. As we know the limitations from the different routes of administration are first-pass metabolism, poor bioavailability, and poor solvency to overcome these limitations Nanostructured lipid carriers (NLCs) were prepared. Transdermals, ocular, oral, topical, and parenteral are the different routes through which Nano based systems are delivered. Spatially incompatible liquid lipids and solid lipids are blended and NLCs were prepared. The main advantages of drug therapy over conventional carriers NLCs are improved bioavailability, increased solubility. This review describes the NLC used for the migraine treatments, its advantages, and disadvantages, types, NLC techniques, mode of action, of NLC. Imperfect, amorphous, and multiple types are the main three types of NLCs. Lipids like solid and liquid, Emulsifiers, and aqueous medium were the excipients used. Micro-emulsion technique, micro-emulsion-based SLN/NLC preparations, solvent diffusion method, high-pressure homogenization (HPH), hot and cold homogenization techniques, and melt emulsification method are the techniques used for the preparation of NLC.
Cite this article:
Swati Lade, Nirmal Shah, Sushil Burle. Nanostructured Lipid Carriers: A Vital Drug Carrier for Migraine Treatment. Research Journal of Pharmacy and Technology. 2022; 15(7):3309-6. doi: 10.52711/0974-360X.2022.00554
Cite(Electronic):
Swati Lade, Nirmal Shah, Sushil Burle. Nanostructured Lipid Carriers: A Vital Drug Carrier for Migraine Treatment. Research Journal of Pharmacy and Technology. 2022; 15(7):3309-6. doi: 10.52711/0974-360X.2022.00554 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-7-76
REFERENCES:
1. Terry J B. Pain Management. Pharmacotherapeutics- A Pathophysiologic Approach, 6th Edition, The McGraw-Hill Companies, Inc. United States, 2005; 1089-110
2. Pasero C, Paice J A, McCaffery M. Basic mechanisms underlying the causes and effects of pain. In: McCaffery M, Pasero C, eds. Pain. St. Louis, Mosby, 1999:15–34
3. Muthyala N, Qadrie Z L, Suman A; Migraine & Migraine Management: A Review; PharmaTutor; 2018; 6(4); 8-17 doi.org: 10.29161/PT.v6.i4.2018.8
4. Sharma A, Baldi A Nanostructured Lipid Carriers: A Review. J Develop Drugs 2018;7: 191.
5. June IM, Davange RM, Salunkhe KS, Chaudhari SR, Deshmukh PD, et al. Nanostructured lipid carrier: Novel drug delivery system. J Adv Drug Deliv.2016; 3: 7-16.
6. Xia Q, Wang H Preparation and characterization of coenzymes Q-10 loaded NLC. NSTI-Nanotech. 2010; 3: 498-501.
7. Nair R, Kumar KSA, Priya KV, Sevukarajan M Recent advances in solid lipid nanoparticle-based drug delivery systems. J Biomed Sci Res 2011; 3: 368-84.
8. Mishra B., Patel, B.B., Tiwari, S., Colloidal nanocarriers: a review on formulation technology, types, and applications toward targeted drug delivery. Nanomedicine.2010; 6(1), 9-24. Doi.org: 10.1016/j.nano.2009.04.008
9. Koo, O.M., Rubinstein, I., Hayat Onyuksel, H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine. 2005; 1(3), 193-212. Doi.org: 10.1016/j.nano.2005.06.004
10. Joshi, M.D., Müller, R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009;71(2), 161-172.doi.org: 10.1016/j.ejpb.2008.09.003
11. Müller RH, Maassen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996; 4:161-70. Doi.org10.3109/10611869609015973
12. Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv. 2014; 5(6):709-33. doi: 10.4155/tde.14.41. PMID: 25090283.
13. Tortora, Gerard J., and Bryan Derrickson. Introduction to the Human Body: The Essentials of Anatomy and Physiology.
14. Puledda, F., Messina, R., & Goadsby, P. J. An update on migraine: current understanding and future directions. Journal of neurology, 2017; 264(9), 2031–2039. https://doi.org/10.1007/s00415-017-8434-y
15. Poojitha Mamindla., et al. “A Review on Migraine”. Acta Scientific Pharmaceutical Sciences 3.1; 2019: 29-42.
16. Muller R.H, Mader K, Lippacher A, Jenning V, Solid-liquid (semi-solid) liquid particles and method of producing highly concentrated lipid particle dispersions, in PCT/EP00/04565. 2000. Eur J Pharm Biopharm. 2000 Jul; 50(1):161-77.doi: 10.1016/s0939-6411(00)00087-4.
17. Saupe A, Wissing S.A, Lenk A, Schmidt C, Muller R.H, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) structural investigations on two different carrier systems. Biomed Mater Eng. 2005; 15: 393-402. PMID: 16179760
18. Raina A.S, Nevine S A, Tahany S, Alia A. B: Formulation of novel oxybenzone – loaded nanostructured lipid carriers, AAPS Pharma Sci-Tech,2010; 11(4):1684-1694.doi.org: 10.1208/s12249-010-9553-2
19. Attama A. A, Momoh M.A, Philip F, Builders Lipid Nanoparticulate Drug Delivery Systems: A Revolution in Dosage Form Design and Development, in tech open space open mind. 2012. Doi.org: 10.5772/50486
20. Subramanian S, Velmurugan.R, Nanostructured Lipid Carriers: A potential drug carrier for cancer chemotherapy, Biomed central,www.lipidworld.com/content/11/1/159.Acess on 25 Sep 2018.
21. Mulle R. H, Radtke M, Wissing S.A, Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Advance drug delivery reviews, 2002; 54 (1): 131-155.doi.org: 10.1016/s0169-409x(02)00118-7
22. Schafer-Korting M, Mehnert W, Korting H. C, lipid nanoparticles for improved topical application of drugs for skin diseases. Advanced Drug Deliv Rev.2007 59: 427- 443.doi.org: 10.1016/j.addr.2007.04.006
23. Bunjes H, Westesen K, Koch M.H, crystallization tendency and polymorphic transition in triglyceride nanoparticles. International Journal of Pharmaceutics, 1996; 129(1): 159-173.doi.org: 10.1016/0378-5173(95)04286-5
24. D. V. Gowda et al, Nano structured lipid carrier based drug delivery system, J. Chem. Pharm. Res, 2016; 8(2): 627-643.
25. R. Shah et al. Composition and structure. Rohan Shah, Daniel Eldridge, Enzo Palombo, Ian Harding (eds). Lipid Nanoparticles: Production, Characterization and Stability, 1st ed. NY, USA: Springer 2015: 11-22.
26. Corrigan O, Healy A. Surfactants in pharmaceutical products and systems. Swarbrick J (ed). Encyclopedia of pharmaceutical technology, 3rd ed. NY, USA, Informa Healthcare, 2006:3583 3596
27. Chia-Lang Fanga, Saleh A. Al-Suwayehb, and Jia-You Fang, Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting, Recent Patents on Nanotechnology, 2013; 7: 41-55. PMID: 22946628.
28. Sawant KK, Dodiya SS. Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv Formul 2008; 2:120-35.
29. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.DOI: 10.1016/s0939-6411(00)00087-4
30. Jores K, Mehnert W, Mäder K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: A nuclear magnetic resonance and electron spin resonance study. Pharm Res 2003; 20:1274-83. Doi.org: 10.1023/A:1025065418309
31. Shidhaye S S, Vaidya R, Sutar S, Patwardhan A, Kadam V J. Solid lipid nanoparticles and nanostructured lipid carriers – innovative generations of solid lipid carriers. Curr Drug Deliv 2008; 5:324-31. 10.2174/156720108785915087
32. Liu C H, Wu CT. Optimization of nanostructured lipid carriers for lutein delivery. Colloid Surf A 2010; 353:149-56.doi.org: 10.1016/j.colsurfa.2009.11.006
33. Mk Sahu, Gc Soni, et al International Journal For Pharmaceutical Research Scholars (Ijprs), 2012, 1(3).
34. Cavalli R, Gasco M. R, Chetoni P, Burgalassi S, Saettone M. F. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238:241-5. 10.1016/s0378-5173(02)00080-7
35. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2005;107:215-28.doi.org: 10.1016/j.jconrel.2005.06.006
36. Sivaramakrishnan R, Nakamura C, Mehnert W, Korting H. C, Kramer K. D, Schäfer-Korting M. Glucocorticoid entrapment into lipid carriers – characterisation by parelectric spectroscopy and influence on dermal uptake. J Control Release 2004; 97:493-502.
37. Lancelot A, Sierra T, Serrano JL. Nanostructured liquid-crystalline particles for drug delivery. Expert Opin Drug Deliv 2014; 11:547-64.doi.org: 10.1517/17425247.2014.884556
38. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366:170-84. Doi.org: 10.1016/j.ijpharm.2008.10.003
39. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit Rev Ther Drug Carrier Syst 2009; 26:523-80. Doi.org: 10.1615/critrevtherdrugcarriersyst.v26.i6.10
40. Moulik S. P, Paul B. K. Structure, dynamics and transport properties of microemulsions. Adv Colloid Interface Sci. 198;78: 99 – 195.doi.org: 10.1016/S0001-8686(98)00063-3
41. Gohla SH, Dingler A. Scaling up feasibility of the production of solid lipid nanoparticles (SLN). Pharmazie. 2001; 56: 61– 63. PMID: 11210672.
42. Schwarz C, Mehnert W, Lucks J S, Muller R H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release. 1994; 30: 83– 96.doi.org: 10.1016/0168-3659(94)90047-7
43. Puglia C , Blasi P , Rizza L , Schoubben A , Bonina F , Rossi C , Ricci M. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm.2008; 357: 295– 304. 10.1016/j.ijpharm.2008.01.045
44. Muller R. H , Radtke M , Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev.2002; 54: 131– 155. Doi.org 10.1016/s0169-409x(02)00118-7
45. Adhikari, Piya, Pal, Paulami, Das, Anup Kr., Ray, Subhabrata, Bhattacharjee, Arpita, Mazumder, Bhaskar, Nano Lipid-Drug Conjugate: An Integrated Review. International Journal of Pharmaceutics 2017; 08(529).doi.org/10.1016/j.ijpharm.2017.07.039
46. Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol. 2016; 44(1):27-40. 10.3109/21691401.2014.909822
47. Rathor S, Bhatt DC, Aamir S, Singh SK, Kumar V. A Comprehensive Review on Role of Nanoparticles in Therapeutic Delivery of Medicine. Pharm Nanotechnol. 2017;5(4):263-275 doi.org: 10.2174/2211738505666171113130639
48. Scholes, P., D., Coombes, A., G., Illum, L., Davis, S., S., Watts, J., F., Ustariz, C., Vert, M., Davies, M., C., Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J. Controlled Release, 1999. 59(3):261-78.doi.org:10.1016/s0168-3659(98)00138-2
49. Vauthier-Holtzscherer, C., Benabbou, S., Spenlehauer, G., Veillard, M., Couvreur, P. “Methodology for the preparation of ultra-dispersed polymer systems”, STP Pharma Sciences, 1991; 1: 109-116.
50. Khosa A, Reddi S and Saha RN: Nanostructured lipid carriers for site-specific drug delivery. Biomedicine and Pharmacotherapy 2018; 103: 598-613.doi.org: 10.1016/j.biopha.2018.04.055
51. Olbrich C, Gessner A, Schroder W, Kayser O and Muller RH: Lipid-drug conjugates nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption. Journal of Controlled Release 2004; 96(3): 425-35.doi.org: 10.1016/j.jconrel.2004.02.024
52. Jain S., Jain N.K. Liposomes as drug carrier, In: Jain NK, editor. Controlled and novel drug delivery. 2nded. CBS publisher, New Delhi, 2002, .304-52.
53. Baba R .Patent and Nanomedicine. Nanomedicine. 2007; 2(3), 351-374.doi.org: 10.2217/17435889.2.3.351
54. Khopde AJ, Jain, NK. Dendrimer as potential delivery system for bioactive In: Jain NK, editor. Advances in controlled and novel drug delivery. CBS publisher, New Delhi, 2001, 361-80. Doi.org: 10.1016/S0378-5173(01)00901-2
55. Rathor S, Bhatt DC, Aamir S, Singh SK, Kumar V. A Comprehensive Review on Role of Nanoparticles in Therapeutic Delivery of Medicine. Pharm Nanotechnol. 2017;5(4):263-275.doi.org: 10.2174/2211738505666171113130639
56. Silverstrini M, cupini LM, calabresi P, Floris R, Bernardi G; Migraine with aura-like syndrome due to arteriovenous malformation. The clinical value of transcranial Doppler in early diagnosis. Cephalalgia, 1992; 12:115-119. Doi.org: 10.1046/j.1468-2982.1992.1202115.x
57. Villalon CM, centurion D, Valdivia LF, De vries P, Saxena PR; An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc west Pharmacol soc, 2002; 45:199-210. Doi.org: 10.1002/(SICI)1096-8628(19980605)77:5<415::AID-AJMG12>3.0.CO;2-L
58. Arulmani U, Gupta S, MaassenVanDenBrink A, Centurión D,Villalón CM, Saxena PR; Experimental migraine models and their relevance in migraine therapy. Cephalalgia, 2006; 26(6):642- 659. doi.org: 10.1111/j.1468-2982.2005.01082.x
59. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125–33. doi.org 10.1016/j.pain.2003.10.008
60. Le Doare K, Akerman S, Holland PR, et al. Occipital aff erent activation of second order neurons in the trigeminocervical complex in rat. Neurosci Lett 2006; 403: 73–77.doi.org: 10.1016/j.neulet.2006.04.049
61. Mitul R. Vasanani, Nisha Patel, Divyakant Patel, Rajesh KS, Lalit Lata Jha. Mucoadhesive-Nanoparticulate System for Ocular Delivery of Loteprednol Etabonate. Asian J. Pharm. Res. 4(2): April-June 2014; Page 78-83.doi.org:10.5958/2231–5691.
62. Vaishali B. Morade, Vandana R. Daga, Dr. Prashant R. Malpure. Formulation and Evaluation of Mouth Dissolving Tablets of Zolmitriptan. Asian J. Pharm. Tech. 2018; 8 (1): 35-42. Doi.org: 10.5958/2231-5713.2018.00006.5
63. Akshat Sharma, Amit Dubey ,Reenu Yadav Solid Lipid Nanoparticles: A Promising Nanotechnology. Research J. Pharma. Dosage Forms and Tech. 2011; 3(5): 167-175. Doi.org
64. Harsh Joshi, Priyanka Ahlawat. Solid Lipid Nanoparticles for nose to Brain delivery: A Review. Res. J. Pharma. Dosage Forms and Tech.2021; 13(1):57-61.doi.org :10.5958/0975-4377.2021.00010.0
65. Svapnil Sanghavi, Misam Polara, Dipil Patel, Ruchita Shah, Jayvadan Patel, Manish Patel. Nanoparticle Drug Delivery to Brain – A Review. Research J. Pharm. and Tech. 2001;5(1): 8-13.doi.org.:10.5958/0974-360X.2018.00522.X
66. Nikita S. Malekar, Sheetal B. Gondkar, Bhushan A. Bhairav, Pinak S. Paralkar, Ravindra B. Saudagar. Development of Naratriptan Hydrochloride In-Situ Nasal Gel. Research J. Pharm. and Tech. 2017; 10(4): 979-985. doi.org: 10.5958/0974-360X.2017.00178.0.